

***Welcome to***  
**FDA/CDRH Training Module**



U.S. Department of Health & Human Services



**U.S. Food and Drug Administration**

Protecting and Promoting *Your Health*



Center for Devices and  
Radiological Health



Global Unique Device  
Identification Database

# HL7 SPL Submission Option Overview

July 2014

*Indira R. Konduri*

**GUDID Program Manager**

**FDA\CDRH\OSB\Informatics Staff**

# Agenda

- GUDID HL7 SPL Submission Process
- FDA Electronic Submissions Gateway
- Submission Acknowledgements
- GUDID HL7 SPL Submission Testing
- Using Third Party Submitters
- HL7 SPL submission Pointers
- Editing HL7 SPL submissions
- How to Contact Us

# Unique Device Identification System

- 2007 FDAAA – the system
- 2012 FDASIA – the timelines
- 2012 Proposal – 77 FR 40736
- 2013 Final Rule– 78 FR 58786

CDRH Learn – [www.fda.gov/CDRHLearn](http://www.fda.gov/CDRHLearn) -- look under **Unique Device Identification (UDI) System** for previous training webinars on:

- The UDI Final Rule
- GUDID Overview
- GUDID Accounts
- GUDID DI Record

Compliance Date	Must bear a UDI & submit data to GUDID
September 24, 2014	<ul style="list-style-type: none"> <li>• Class III devices, incl. class III stand alone software</li> <li>• Devices licensed under the PHS Act</li> </ul>
September 24, 2015	<ul style="list-style-type: none"> <li>• Implantable, life-supporting and life-sustaining (I/LS/LS) devices, incl. stand alone software</li> <li>• Direct Marking of I/LS/LS for certain intended uses</li> </ul>
September 24, 2016	<ul style="list-style-type: none"> <li>• Class II devices</li> <li>• Direct Marking for class III devices and devices licensed under the PHS Act, for certain intended uses</li> </ul>
September 24, 2018	<ul style="list-style-type: none"> <li>• Class I devices and devices not classified class I, II or III</li> <li>• Direct Marking of class II devices for certain intended uses</li> </ul>
September 24, 2020	<ul style="list-style-type: none"> <li>• Direct Marking of class I devices and devices not classified into class I, II or III, for certain intended uses</li> </ul>

# UDI = Unique Device Identifier

- Device Identifier(DI) + Production Identifier(s)(PI)
- DI= mandatory, fixed portion of a UDI that identifies the specific version or model of a device and the labeler of that device
- PI= a conditional, variable portion of a UDI that identifies one or more of the following when included on the label of the device:
  - Lot or batch number
  - Serial number
  - Expiration date
  - Manufacturing date
  - For an HCT/P regulated as a device, the distinct identification code


# GUDID

Global Unique Device  
Identification Database

- Repository of key device identification information
- Contains ONLY the DI; PIs are **not** submitted to or stored in the GUDID
  - Contains only PI flags to indicate which PI attribute(s) are on the device label


# DI Record

DI Record = Device Identifier (DI) + GUDID attributes





# GUDID Overview



# GUDID HL7 SPL Submission Option

- HL7 = Health Level 7
- SPL = Structured Product Labeling
- Submission of device information as xml files, one DI record at a time
- Technical specifications available on the UDI website
- Submissions sent via the FDA Electronic Submissions Gateway (ESG)
- **Testing required** prior to production submission



# HL7 SPL Submission – Process

- Register with the FDA ESG
- Complete ESG testing
- Request a test GUDID Account
- Complete GUDID HL7 SPL testing
- Request and obtain a production GUDID Account
- Submit DI records

# FDA ESG

- Enables secure receipt of regulatory submissions
- Routes submissions to the appropriate Center
- Two options for submission
  - WebTrader (Low Volume)
  - B2B (High Volume)
- Acknowledgements for each stage of report transmission
- [www.fda.gov/esg](http://www.fda.gov/esg)



FDA Electronic  
Submissions  
Gateway

# Acknowledgements



Original slide courtesy of Eugene Reilly, FDA\CDRH

# Acknowledgements

## Ack1/Receipt/MDN

This MDN (Message Disposition Notification) was automatically built on Tue, 25 Mar 2014 23:36:26 GMT in response to a message with id <20425118.41395790583689> JavaMail: John.ADAMS@ABC1234567> received from ZZFDATST on Tue, 25 Mar 2014 23:36:25 GMT. Unless stated otherwise, the message to which this MDN applies was successfully processed.

## Ack2

MessageId:<20425118.41395790583689> JavaMail: John.ADAMS@ABC1234567>  
 CoreId: ci1395790584826.2538@fdsul05622\_te2  
 DateTime Receipt Generated: 03-25-2014, 19:36:52  
 File Count: 1 Directory Count: 2  
 CDRH has received your submission

## Ack3

```
- <submission>
  <coreId>ci1395790584826.2538@fdsul05622_te2</coreId>
  <batchId>2</batchId>
  <dateEntered>03-25-2014, 19:36:52</dateEntered>
  <numReportFailed>0</numReportFailed>
  <numReportPassed>1</numReportPassed>
- <report id="11111111100010">
  <status>passed</status>
</report>
</submission>
```

<html><body><p>Unidentified or unparseable submission type [CoreID]</p></body></html>

# FDA ESG and GUDID

- Request a test ESG account
  - Obtain a digital certificate
  - Send a letter of non- repudiation
- Complete ESG testing
  - Connectivity test
  - Load test
- Existing test accounts can be used
- Be sure to specify- -
  - Center = CDRH
  - Submission Type = GUDID



# GUDID HL7 SPL Testing



- Generate your DI records as xml files
- Request a test GUDID account
  - same account request process – indicate you need a test account
- Do thorough testing via your ESG test account
- Complete the required test scenarios
- Request to move to production submissions via the FDA UDI Help Desk
  - Send Primary DI and coreID with your request
- FDA Staff will review your submission and give you the green- light for production submissions



# Using Third-Party Submitters

- Third- parties may- -
  - Provide software solution/tool to the labeler to generate HL7 SPL xml files; labeler sends submission via ESG
    - Labeler obtains the test ESG account
  - Provide end- to- end solution – generate GUDID data as HL7 SPL xml files AND send submissions via the ESG on behalf of labeler
    - Third- party has the ESG test account
    - Labeler sends a letter of non- repudiation indicating third- party is authorized to submit on their behalf
- Provide third- party information during GUDID account request

# Using Third-Party Submitters

- We are enabling third- parties to test HL7 SPL solutions
- If you use a third- party who has completed testing their solution, must still test with your data
- Labeler is responsible for fulfilling GUDID submission requirements–
  - ensuring submissions are received and processed by the FDA.
  - reporting within the required timeframe
  - record keeping

# If you are a Third-Party Solution Provider...

- May test your GUDID HL7 SPL submission solution independently of Labelers
  - Request a GUDID test Account - indicate it is for HL7 SPL testing
  - Dummy data for certain required attributes will be provided for testing purposes ONLY, upon request
  - GUDID Production accounts NOT provided
- As you work with labelers, must complete GUDID HL7 SPL testing with each labeler

# GUDID HL7 SPL Pointers

- Important to read “GUDID Guidance for Industry and FDA Staff” document
- Allow adequate time for ESG set- up and testing
- When submitting via ESG, please specify Center = *CDRH*, Submission Type = *GUDID*
- GUDID testing completion criteria is the bare minimum
  - Please do thorough internal testing to ensure the scenarios appropriate for your products are accounted for
- Do not submit sample message in the HL7 SPL implementation package as a test submission – it is not validated

# GUIDID HL7 SPL Pointers

- Draft DI record state is not available
- Records can be submitted as –
  - Unpublished – DI Record Publish Date > today
  - Published – DI Record Publish Date <= today
- Can review your submission via the Web Interface
  - Login as a Labeler Data Entry (LDE) user
  - Labeler DUNS number for that DI record should be assigned to you

Device Identifier Record History			
Last Modified Date	Time	DI #	Modified By
Mar 21, 2014	5:03 PM	10020030050373	SPL USER

# GUDID HL7 SPL Pointers

- Submission Folder Structure must be followed
  - Top level folder must be uniquely named
  - Lower level folder must always be named “spl”
  - The GUDID HL7 SPL xml submission file must be named “submission.xml”
  - Do not include any other files in the “spl” folder
- Only one submission (one DI record) in each folder structure



# Editing HL7 SPL Submissions

- Submit the entire DI record, i.e., include changed and unchanged attributes
  - document.setID – links submission edits to the prior submissions
  - document.versionNumber – increment by 1; the highest number will be considered the most recent
  - DI record will be over- written with the most recent file

# Editing DI records

- Use the same submission option used for initial DI record entry for all edits to the DI record
- Unpublished DI Record
  - Initial entry via Web Interface → CANNOT edit via HL7 SPL Option
  - Initial entry via HL7 SPL → may edit via Web Interface
- Published DI Record
  - During grace period
    - Initial entry via Web Interface → CANNOT edit via HL7 SPL Option
    - Initial entry via HL7 SPL → may edit via Web Interface
  - After grace period
    - Initial entry via Web Interface → CANNOT edit via HL7 SPL
      - **Planned enhancement to allow this capability**
    - Initial entry via HL7 SPL → may edit via Web Interface




# Edits to New DI Trigger attribute After Grace Period

- Expected to be an extremely rare occurrence
  - BEFORE publishing a DI record, make sure your data is accurate and “ready” to be *Published*
- However, if necessary to edit AFTER grace period–
  - Contact FDA UDI Help Desk with your request
  - FDA Staff will review your request and change the DI record to “Unpublished” state
  - You can make your edits and then Publish the record

# DI Record Submission

- Start by submitting your records as “unpublished” DI records
- Work with us on data quality review
- Make edits as necessary
- Publish your DI records

# GUDID System Status

- Scheduled downtimes will be posted on [www.fda.gov/udi](http://www.fda.gov/udi), look for GUDID System Status
- Unscheduled downtimes
  - Visit [www.fda.gov/udi](http://www.fda.gov/udi) for information
  - If no information, report issue via Help Desk
- Subscribe to GUDID Email Alerts 

# How to Contact Us

- Contact FDA ESG, [esghelpdesk@fda.hhs.gov](mailto:esghelpdesk@fda.hhs.gov)
  - FDA ESG questions, account set up
  - Ack1/Ack2 issues
- Contact FDA UDI Help Desk
  - HL7 SPL submission option process, questions
  - Ack3 issues
  - GUDID Account Request – production and test
  - Regulatory questions
  - Technical questions

# FDA UDI Help Desk

- Submit question via the web, [www.fda.gov/udi](http://www.fda.gov/udi)
- Please complete all fields on the web form!

## FDA UDI Help Desk

The FDA UDI Help Desk is the primary way to obtain information and assistance on the UDI program and the GUDID. Labelers and GUDID users are encouraged to use the help desk to submit all questions related to UDI and the GUDID. Please complete the information below to submit a UDI support question/comment. Once the question is received, an FDA UDI Help Desk analyst will respond to you as soon as possible.

First Name:\*

Last Name:\*

Organization:\*

Email:\*

Phone:\*

Subject:\*

Question:\*

Type:\*

Fields marked with \* are REQUIRED

# FDA UDI Help Desk

- Question becomes a “case” in help desk tool
- Response will be sent to the email you provide
  - Ask follow-up questions by responding to the email, will append the “case”
- Please ensure you can receive emails from help desk – check your spam folder

# Questions?

For questions on all things UDI/GUDID:  
FDA UDI Help Desk, [www.fda.gov/udi](http://www.fda.gov/udi)

For Questions on FDA ESG:  
[esghelpdesk@fda.hhs.gov](mailto:esghelpdesk@fda.hhs.gov)

Division of Industry and Consumer  
Education: [DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)

[CDRHQuestions@fda.hhs.gov](mailto:CDRHQuestions@fda.hhs.gov)